Amphastar Pharmaceuticals, Inc. (AMPH)
USD 25.23
(-5.19%)
USD 25.23
(-5.19%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.51 Billion USD | 103.9% |
| 2022 | 741.98 Million USD | 10.49% |
| 2021 | 671.52 Million USD | 6.38% |
| 2020 | 631.23 Million USD | 7.54% |
| 2019 | 586.97 Million USD | 14.29% |
| 2018 | 513.56 Million USD | 12.95% |
| 2017 | 454.66 Million USD | 6.3% |
| 2016 | 427.73 Million USD | 9.64% |
| 2015 | 390.13 Million USD | 0.2% |
| 2014 | 389.37 Million USD | 14.94% |
| 2013 | 338.74 Million USD | 6.7% |
| 2012 | 317.47 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.57 Billion USD | 4.06% |
| 2024 Q2 | 1.49 Billion USD | -5.26% |
| 2023 Q2 | 1.37 Billion USD | 78.15% |
| 2023 Q4 | 1.51 Billion USD | -2.05% |
| 2023 FY | 1.51 Billion USD | 103.9% |
| 2023 Q1 | 773.65 Million USD | 4.27% |
| 2023 Q3 | 1.54 Billion USD | 12.07% |
| 2022 Q4 | 741.98 Million USD | 2.1% |
| 2022 Q3 | 726.69 Million USD | 0.41% |
| 2022 FY | 741.98 Million USD | 10.49% |
| 2022 Q1 | 716.23 Million USD | 6.66% |
| 2022 Q2 | 723.71 Million USD | 1.04% |
| 2021 Q3 | 651.67 Million USD | -2.11% |
| 2021 Q2 | 665.74 Million USD | 3.1% |
| 2021 Q1 | 645.73 Million USD | 2.3% |
| 2021 FY | 671.52 Million USD | 6.38% |
| 2021 Q4 | 671.52 Million USD | 3.05% |
| 2020 Q2 | 600.05 Million USD | 4.75% |
| 2020 Q3 | 613.71 Million USD | 2.28% |
| 2020 Q4 | 631.23 Million USD | 2.85% |
| 2020 FY | 631.23 Million USD | 7.54% |
| 2020 Q1 | 572.83 Million USD | -2.41% |
| 2019 Q1 | 544.71 Million USD | 6.07% |
| 2019 FY | 586.97 Million USD | 14.29% |
| 2019 Q4 | 586.97 Million USD | 0.23% |
| 2019 Q3 | 585.63 Million USD | -2.61% |
| 2019 Q2 | 601.3 Million USD | 10.39% |
| 2018 Q1 | 449.78 Million USD | -1.07% |
| 2018 FY | 513.56 Million USD | 12.95% |
| 2018 Q4 | 513.56 Million USD | 6.85% |
| 2018 Q3 | 480.64 Million USD | 6.42% |
| 2018 Q2 | 451.64 Million USD | 0.41% |
| 2017 Q4 | 454.66 Million USD | 3.86% |
| 2017 FY | 454.66 Million USD | 6.3% |
| 2017 Q1 | 435.61 Million USD | 1.84% |
| 2017 Q2 | 443.99 Million USD | 1.92% |
| 2017 Q3 | 437.76 Million USD | -1.4% |
| 2016 Q1 | 395 Million USD | 1.25% |
| 2016 FY | 427.73 Million USD | 9.64% |
| 2016 Q4 | 427.73 Million USD | -0.26% |
| 2016 Q3 | 428.83 Million USD | 4.96% |
| 2016 Q2 | 408.58 Million USD | 3.44% |
| 2015 Q3 | 395.02 Million USD | -0.98% |
| 2015 Q2 | 398.92 Million USD | 0.61% |
| 2015 Q1 | 396.5 Million USD | 1.83% |
| 2015 FY | 390.13 Million USD | 0.2% |
| 2015 Q4 | 390.13 Million USD | -1.24% |
| 2014 Q4 | 389.37 Million USD | -2.93% |
| 2014 Q3 | 401.13 Million USD | 0.97% |
| 2014 Q2 | 397.26 Million USD | 15.11% |
| 2014 Q1 | 345.1 Million USD | 1.88% |
| 2014 FY | 389.37 Million USD | 14.94% |
| 2013 Q3 | 345.39 Million USD | 0.0% |
| 2013 Q4 | 338.74 Million USD | -1.93% |
| 2013 Q1 | - USD | -100.0% |
| 2013 FY | 338.74 Million USD | 6.7% |
| 2012 Q4 | 317.47 Million USD | 0.0% |
| 2012 FY | 317.47 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cosmos Health Inc. | 66.29 Million USD | -2182.071% |
| Safety Shot Inc | 12.7 Million USD | -11804.088% |
| Bright Green Corporation | 17.4 Million USD | -8593.374% |
| Embecta Corp. | 1.21 Billion USD | -24.581% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | -67.279% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -2534.909% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | -32.328% |
| Dynavax Technologies Corporation | 997.09 Million USD | -51.732% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -635.151% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | -107.733% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 3.905% |
| PainReform Ltd. | 9.93 Million USD | -15135.77% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -5432.286% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -5432.286% |
| SCYNEXIS, Inc. | 128.41 Million USD | -1078.17% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -6441.74% |
| Journey Medical Corporation | 76.84 Million USD | -1868.681% |
| Alpha Teknova, Inc. | 128.58 Million USD | -1076.567% |
| Procaps Group, S.A. | 460.18 Million USD | -228.76% |
| Theratechnologies Inc. | 77.76 Million USD | -1845.392% |
| Harrow Health, Inc. | 311.75 Million USD | -385.289% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -10058.544% |
| Biofrontera Inc. | 27.93 Million USD | -5316.411% |
| DURECT Corporation | 45.18 Million USD | -3247.965% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -7.377% |
| Cronos Group Inc. | 1.13 Billion USD | -33.384% |
| OptiNose, Inc. | 107.72 Million USD | -1304.368% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | -221.163% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -2604.091% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -6464.425% |
| Organogenesis Holdings Inc. | 460.02 Million USD | -228.876% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -12594.156% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -1750.067% |
| Radius Health, Inc. | 1.71 Billion USD | 11.832% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -2739.175% |
| ProPhase Labs, Inc. | 91.92 Million USD | -1545.775% |
| Phibro Animal Health Corporation | 982.18 Million USD | -54.035% |
| Procaps Group S.A. | 460.18 Million USD | -228.76% |
| Alvotech | 950.09 Million USD | -59.239% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -3393.297% |
| Viatris Inc. | 47.68 Billion USD | 96.827% |
| Rockwell Medical, Inc. | 52.17 Million USD | -2799.799% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -1181.097% |
| SIGA Technologies, Inc. | 254.83 Million USD | -493.68% |
| Tilray Brands, Inc. | 4.33 Billion USD | 65.102% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -452.759% |
| Shineco, Inc. | 84.17 Million USD | -1697.248% |
| PetIQ, Inc. | 868.22 Million USD | -74.253% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -17829.298% |
| Incannex Healthcare Limited | 17.04 Million USD | -8774.946% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 53.469% |
| Alimera Sciences, Inc. | 153.52 Million USD | -885.456% |
| Silver Spike Investment Corp. | 88.57 Million USD | -1608.033% |
| Assertio Holdings, Inc. | 286.41 Million USD | -428.216% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -25319.676% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -4376.628% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -4742.403% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -11320.326% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -479.38% |
| Hempacco Co., Inc. | 18.04 Million USD | -8284.999% |
| Talphera, Inc. | 20.39 Million USD | -7318.053% |
| Alvotech | 950.09 Million USD | -59.239% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | -272.492% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 8.372% |
| Currenc Group, Inc. | 141.49 Million USD | -969.268% |
| Kamada Ltd. | 351.96 Million USD | -329.841% |
| Indivior PLC | 1.95 Billion USD | 22.464% |
| Evoke Pharma, Inc. | 7.06 Million USD | -21303.44% |
| Flora Growth Corp. | 23.62 Million USD | -6303.589% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -11320.326% |
| Evolus, Inc. | 188.99 Million USD | -700.491% |
| HUTCHMED (China) Limited | 1.27 Billion USD | -18.217% |
| Akanda Corp. | 8.83 Million USD | -17014.403% |